Novartis joins Malaria No More in campaign to eliminate malaria
25 April 2013
Novartis and the charity Malaria No More have announced that they
will work together to accelerate progress in the fight against
malaria in a campaign called the Power of One.
Novartis will give financial support and donate up to three
million courses of its paediatric antimalarial drug to match the
treatments donated by the public.
The Power of One campaign aims to address the global treatment
gap for malaria over three years through direct donations and
existing government commitments.
"We believe that this innovative campaign will help speed malaria
elimination," said Joseph Jimenez, Novartis Chief Executive Officer.
"Novartis has been striving towards this goal for more than a
decade, and we just reached the milestone of providing 600 million
treatments without profit to patients in malaria-endemic countries.
No one should die from malaria today."
"The Power of One campaign challenges the global public to help
close the global treatment gap for malaria; Every dollar raised will
buy and deliver a full course of life-saving child treatment," said
Martin Edlund, CEO of Malaria No More. "We are delighted to be
partnering with forward-thinking companies like Novartis to help end
deaths from this disease-one dollar and one child at a time."
Novartis has joined the Power of One campaign with some of the
world's most innovative companies, including Alere who will be
providing malaria rapid diagnostic tests, along with Time Warner,
Twitter and others. The campaign will use the latest social, mobile,
and e-commerce technologies to rally the global public to contribute
to the campaign.
"Malaria is a complex issue and needs a multi-pronged
collaborative approach. We can't solve a problem like this on our
own," said Linus Igwemezie, Head of the Novartis Malaria Initiative.
"Through partnerships, with organizations like Malaria No More, we
can speed up progress toward the ultimate goal of malaria
Novartis reaches 600 million treatment deliveries
Power of One builds on the Novartis Malaria Initiative's efforts
to eliminate malaria. Since 2001, a key focus of the company's
commitment has been to supply its artemisinin-based combination
therapy (ACT) to malaria-endemic countries. It has delivered 600
million ACT treatments without profit to the public sector of more
than 60 malaria-endemic countries. This includes the provision of
more than 150 million treatments of the antimalarial especially
developed for children. Never before have so many treatments been
distributed in such a short time frame to assist children suffering
Novartis has two new classes of anti-malaria
drugs in development. The most advanced compound is in Phase II
clinical trials. For more information visit,
For more information about the Power of One campaign see